Drugmaker Eli Lilly has capped the monthly out-of-pocket cost of insulin at $35. The change takes effect immediately and pressures other pharmaceutical companies to follow.
The decision follows the Inflation Reduction Act's $35 cap for seniors enrolled in Medicare and applies to millions of insured or uninsured Americans.
The company first started the $35 cap in 2020 due to the pandemic, so the announcement opens an existing opportunity to all people with need for any of Eli Lilly’s insulin products.